The FDA approved a drug as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the E. coli-derived asparaginase products used most commonly for treatment.
Read more: FDA Approves Component of Treatment Regimen for Most Common Childhood Cancer